By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TWi Pharmaceuticals, Inc. 

4F, No. 41, Lane 221
Kang Chien Rd.
Nei Hu Dist.  Taipei  114 
Phone: 886-2-26573350 Fax: 886-2-26573391


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
TWi Pharmaceuticals, Inc. Announces That It Will Sell Its Products In The U.S. Market, Originally Planned To Be Sold By Teva, Through Its Wholly-Owned Subsidiary, TWi Pharmaceuticals USA 2/24/2015 6:52:20 AM
Supernus Pharmaceuticals (SUPN) Sues TWi Pharmaceuticals, Inc. For Infringement Of Oxtellar XR® Patents 1/22/2015 8:14:41 AM
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014 7:24:31 AM
TWi Pharmaceuticals, Inc. Receives U.S. FDA Approval On Generic Donepezil Hydrochloride Tablets USP, 23 Mg, Its Fifth ANDA From U.S. FDA 10/30/2014 7:41:56 AM
TWi Pharmaceuticals, Inc. Receives FDA Final Approval On Generic Megestrol Acetate 125mg/Ml Oral Suspension 8/28/2014 11:14:55 AM
TWi Pharmaceuticals, Inc. Announces Settlement Of Lidoderm® Patent Litigation 4/23/2014 8:58:31 AM
TWi Pharmaceuticals, Inc.i Announces ANDA Approval Of Generic Procardia Xl® Tablets 30 Mg, 60 Mg And 90 Mg In The United States 4/7/2014 9:28:15 AM
TWi Pharmaceuticals, Inc. Receives Patent Allowance for Its Reduced Food Effect Metformin Controlled Release Formulation in United States 7/16/2013 10:39:53 AM
TWi Pharmaceuticals, Inc.' Manufacturing Site for the Generic Version of Lidoderm(R) (Lidocane 5% patch) Passes US FDA cGMP Audit and Pre-Approval Inspection 5/29/2013 10:05:00 AM
TWi Pharmaceuticals, Inc. Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets 5/14/2013 9:35:08 AM
12
//-->